Drug Trial Radar · NCT06505031
A Study of TAK-861 in People With Narcolepsy Type 1
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Oct 8, 2024
Primary completion
Jun 4, 2025
Study completion Jun 4, 2025
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jul 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms and daily life functions; and to learn about the safety of TAK-861.
Conditions
- Narcolepsy Type 1
Interventions
TAK-861Drug
Oral tablet.
PlaceboDrug
TAK-861-matching placebo tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake TrialsTime frame: Baseline, Week 12
- Change From Baseline to Week 12 in ESS Total ScoreTime frame: Baseline, Week 12
Locations
28 sites in 11 countries. Site status is shown where the registry gives one.
Takeda Site 1
Glebe, New South Wales, Australia
Takeda Site 22
Linz, Austria
Takeda Site 2
Alken, Belgium
Takeda Site 3
Erpent, Belgium
Takeda Site 25
Ghent, Belgium
Takeda Site 24
Leuven, Belgium
Takeda Site 23
Liège, Belgium
Takeda Site 26
Guangdong, China
Takeda Site 4
Beijing, Beijing Municipality, China
Takeda Site 27
Zhengzhou, Henan, China
Takeda Site 28
Shanghai, Shanghai Municipality, China
Takeda Site 20
Helsinki, Finland
Takeda Site 21
Tampere, Finland
Takeda Site 6
Bron, France
Takeda Site 14
Marseille, France
Takeda Site 5
Montpellier, France
Takeda Site 15
Nantes, France
Takeda Site 16
Léon, Bordeaux, France
Takeda Site 7
Bologna, Italy
Takeda Site 17
Pozzilli, Italy
Takeda Site 8
Roma, Italy
Takeda Site 9
Krakow, Poland
Takeda Site 12
Seoul, South Korea
Takeda Site 11
Seoul, Daegu, South Korea
Takeda Site 10
Suwon, Gyeonggi-do, South Korea
28003
Barcelona, Spain
Takeda Site 13
Madrid, Spain
Takeda Site 19
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.